- 01Stronger per milligram, similar outcomes
Rosuvastatin lowers LDL about as much at 20 mg as atorvastatin does at 40 to 80 mg, but in LODESTAR the two drugs gave similar 3-year rates of death, heart attack, stroke or artery procedures, and rosuvastatin brought slightly more new diabetes and cataract surgery.
- 02So the way the body clears it is what decides the dose
Rosuvastatin barely uses the CYP3A4 enzyme, so grapefruit matters little; its levels depend on the OATP1B1 and BCRP transporters and the kidneys, which is why Asian ancestry and severe kidney disease mean a 5 mg start and cyclosporine means a 5 mg cap.
Rosuvastatin is the statin prescribers reach for when they want a large LDL drop from a small tablet: 20 mg does roughly what 40 to 80 mg of atorvastatin does 2 3. In LODESTAR, a 4,400-person trial that compared the two drugs on heart attacks and strokes, that extra strength gave no fewer events and a little more new diabetes 5. Because the extra strength buys no extra protection, what matters day to day is how the body clears rosuvastatin, through transporters and the kidneys rather than the CYP3A4 liver enzyme: that route sets who starts at 5 mg, which medicines cap the dose and why grapefruit barely matters.
What rosuvastatin is and how it works
Rosuvastatin is a prescription statin, sold as Crestor since its US approval in 2003 1 and now also as a low-cost generic. It blocks HMG-CoA reductase, the enzyme the liver uses to make cholesterol. Liver cells respond by adding LDL receptors to their surface and pulling LDL particles out of the blood 1. The US label lists it for lowering the chance of heart attack, stroke and artery procedures in adults at raised risk, for high cholesterol, including the inherited form, familial hypercholesterolemia, and for slowing the build-up of artery plaque 1. The statins guide covers the drug class as a whole.
Atorvastatin and simvastatin are broken down by CYP3A4, a liver enzyme that grapefruit and many antibiotics block. Rosuvastatin barely touches that enzyme. Its blood level depends on two transporter proteins, OATP1B1 and BCRP, and to a smaller degree on the kidneys 1.
How the body handles rosuvastatin, and why that sets the dose
How much does rosuvastatin lower LDL?
In STELLAR, a 6-week trial that compared statins dose for dose in 2,431 adults with high cholesterol, rosuvastatin lowered LDL cholesterol by an average of 46 percent at 10 mg, 52 percent at 20 mg and 55 percent at 40 mg 3. Pooled trials put 5 mg at about 41 percent 10. The ACC/AHA intensity bands, set in the 2018 guideline, call a 30 to 49 percent drop moderate intensity, which covers rosuvastatin 5 and 10 mg, and a drop of 50 percent or more high intensity, which covers 20 and 40 mg 2. The 2026 guideline that replaced it judges treatment mainly by LDL goals set by risk 7.
| Daily dose | Average LDL drop (STELLAR at 6 weeks; 5 mg from pooled trials) | Intensity (ACC/AHA) | Example: LDL starting at 160 mg/dL (4.1 mmol/L) |
|---|---|---|---|
| 5 mg | About 41% 10 | Moderate 2 | About 94 mg/dL (2.4 mmol/L) |
| 10 mg | 46% 3 | Moderate 2 | About 86 mg/dL (2.2 mmol/L) |
| 20 mg | 52% 3 | High 2 | About 77 mg/dL (2.0 mmol/L) |
| 40 mg | 55% 3 | High 2 | About 72 mg/dL (1.9 mmol/L) |
Each doubling of the dose adds only 3 to 6 percentage points to the LDL drop 3, and individual results scatter widely around the averages. Apolipoprotein B (ApoB, a count of all LDL-type particles) and non-HDL cholesterol fall too, by a somewhat smaller percentage than LDL; triglycerides fall by about a fifth to a quarter and HDL rises by about 8 to 10 percent 3. The ApoB vs LDL comparison explains which to trust when they disagree. Lipoprotein(a), an inherited particle, does not fall on statins and can rise slightly 13, so a high Lp(a) stays high on treatment.
Rosuvastatin vs atorvastatin: which is stronger, and does it matter?
Milligram for milligram, rosuvastatin is roughly three times as strong as atorvastatin, by one pooled estimate 10. The ACC/AHA bands put rosuvastatin 5 to 10 mg in the same moderate band as atorvastatin 10 to 20 mg, and rosuvastatin 20 to 40 mg beside atorvastatin 40 to 80 mg 2. The atorvastatin guide covers that drug's own dose table.
The extra strength did not translate into fewer events in LODESTAR. Among 4,400 adults with coronary artery disease in South Korea followed for 3 years, death, heart attack, stroke or an artery procedure happened to 8.7 percent on rosuvastatin and 8.2 percent on atorvastatin, a difference within the play of chance 5. Rosuvastatin reached slightly lower LDL, and more people on it developed diabetes needing medicine (7.2 vs 5.3 percent) or had cataract surgery (2.5 vs 1.5 percent) 5.
Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery compared with atorvastatin.Lee YJ et al., LODESTAR trial, BMJ, 2023 5
Rosuvastatin or atorvastatin: similar outcomes, handled differently
Related compounds
Does rosuvastatin prevent heart attacks and strokes?
JUPITER tested rosuvastatin 20 mg against placebo in 17,802 people without heart disease whose LDL was under 130 mg/dL but whose hs-CRP, a blood marker of inflammation, was 2 mg/L or higher 4. It stopped early, at a median of 1.9 years, with 142 first heart attacks, strokes, artery procedures, hospital stays for worsening chest pain (unstable angina) or cardiovascular deaths on rosuvastatin against 251 on placebo 4.
| Trial | Who took part | Comparison | Result |
|---|---|---|---|
| HOPE-3 | 12,705 people at intermediate risk without heart disease | 10 mg vs placebo | Cardiovascular death, heart attack or stroke in 3.7% vs 4.8% over a median 5.6 years, about 11 fewer per 1,000 people 9 |
| LODESTAR | 4,400 adults with coronary artery disease | Rosuvastatin vs atorvastatin | Death, heart attack, stroke or artery procedure in 8.7% vs 8.2% over 3 years 5 |
| ASTEROID | Adults with coronary artery disease having artery ultrasound | 40 mg, no comparison group | Average LDL about 61 mg/dL; plaque volume shrank slightly over 2 years 12 |
Across statin trials, each 1 mmol/L (39 mg/dL) fall in LDL cuts major cardiovascular events by about 22 percent 11, so a 50 percent LDL drop is not a 50 percent drop in risk. How much one person gains depends on starting risk, and a coronary calcium score can help sort out people whose risk sits in the grey zone.
How to take rosuvastatin
Rosuvastatin is taken once a day at any time, with or without food, and swallowed whole 1. With a half-life of about 19 hours, blood levels are the same after morning or evening doses 1, so unlike simvastatin it need not be a bedtime tablet. LDL is close to its full drop by 4 weeks 1. If a dose is missed, the US label says not to take an extra one and to take the next dose at the usual time; after taking too much, get medical help or call a poison center (in the US, 1-800-222-1222) 1.
How rosuvastatin is taken, from the US label
The label's dose range is 5 to 40 mg a day, chosen from the LDL level and heart risk 1. The effect lasts only while the tablet is taken, so LDL drifts back toward its old level after stopping, and stopping is a decision to make with the prescriber.
Rosuvastatin side effects
The side effects reported most often on the rosuvastatin label are headache, nausea, muscle aches, weakness and constipation 1. Most muscle aches on a statin, though, are not caused by the drug 8.
In 19 blinded trials, 27.1 percent on a statin and 26.6 percent on placebo reported muscle pain or weakness; only about 1 in 15 first-year reports was caused by the statin.
Blood sugar
Rosuvastatin nudges blood sugar up 1. In JUPITER, doctors reported new diabetes in 3.0 percent of people on rosuvastatin and 2.4 percent on placebo 4, and in LODESTAR it was more common than on atorvastatin 5. In a 2024 pooled analysis of blinded statin trials, most extra diagnoses were in people whose blood sugar was already near the diabetes line 14, such as those with prediabetes. An HbA1c result from before starting shows where a person begins.
Protein or blood in the urine
The rosuvastatin label lists a urine finding: protein and microscopic blood on a dipstick test, seen more often at 40 mg, usually passing and not linked to worse kidney function 1. If it persists without another explanation, the label advises the prescriber to consider a lower dose 1. A urine protein to creatinine ratio puts a number on a positive dipstick.
Liver and rare muscle damage
Rises in ALT, a liver enzyme (liver enzymes explained), happen in a small share of people; the label suggests considering a liver test before starting and again when clinically indicated, such as when symptoms suggest a problem 1. Serious muscle breakdown (rhabdomyolysis) is rare, and so is immune-mediated necrotizing myopathy, an autoimmune muscle disease that continues after the statin stops 1. The label's risk factors for muscle damage include age 65 or over, an untreated underactive thyroid, kidney disease, Asian ancestry, higher doses and some other medicines 1.
Aching muscles on rosuvastatin: what prescribers usually check and try
- 1Telling the prescriberDescribe where the aches are, when they began and what else changed, such as new exercise or a new medicine. If the pain comes with weakness, fever or dark urine, call the prescriber the same day; they will say whether to hold the next dose until a CK result is back.
- 2CK and, if suggested, a thyroid testA creatine kinase (CK) test shows whether muscle is breaking down, and what a high CK means explains the cut-offs. A thyroid test (TSH) may be added, since an untreated underactive thyroid raises statin muscle risk 1.
- 3A supervised pause, then a retryThe prescriber may suggest a short break followed by a retry, sometimes at a lower dose, on alternate days or on a different statin. This separates the drug's effect from the background aches that blinded trials record on placebo too 8. Stopping on your own is not part of this.
- 4A lower dose, or a lower dose plus ezetimibeIn RACING, rosuvastatin 10 mg plus ezetimibe matched rosuvastatin 20 mg alone on heart events, and fewer people stopped or cut back because of side effects 6.
Low-function variants in SLCO1B1 and ABCG2, the genes behind its two transporters, raise its blood level, and the CPIC (Clinical Pharmacogenetics Implementation Consortium) guideline, which turns gene results into statin prescribing advice, suggests a lower starting dose of rosuvastatin for people with poor-function results 15. CoQ10 is sometimes tried for statin muscle aches; small trials disagree on whether it helps, and the CoQ10 guide covers them.
Interactions, grapefruit, alcohol and pregnancy
Rosuvastatin's interactions run mostly through its transporters, so its list differs from atorvastatin's. Among the limits the current US label sets 1:
| Medicine or food | What happens | Label guidance |
|---|---|---|
| Cyclosporine (transplant and immune medicine), darolutamide (prostate cancer), belumosudil, vadadustat | Rosuvastatin levels rise 2.5- to 7-fold | Maximum 5 mg a day 1 |
| Gemfibrozil (a cholesterol medicine) | Levels rise and muscle risk adds up | Avoid; if unavoidable, start at 5 mg, maximum 10 mg 1 |
| Atazanavir or lopinavir boosted with ritonavir (HIV), and several hepatitis C combinations | Rosuvastatin levels rise | Start at 5 mg, maximum 10 mg; ledipasvir/sofosbuvir and sofosbuvir/velpatasvir/voxilaprevir are to be avoided 1 |
| Teriflunomide (multiple sclerosis), capmatinib, enasidenib, momelotinib, regorafenib (cancer and blood medicines) | Rosuvastatin levels rise, about 2- to 3.4-fold where measured | Maximum 10 mg a day 1 |
| Febuxostat (gout), fostamatinib (low platelets), ticagrelor (an anti-clotting heart medicine) | Rosuvastatin levels about double | Maximum 20 mg a day 1 |
| Tafamidis (a heart amyloid medicine) | Rosuvastatin levels rise | Avoid; if unavoidable, start at 5 mg, maximum 20 mg 1 |
| Warfarin | INR, the clotting-time measure, can rise | INR before starting, then often until stable after any dose change or stopping 1 |
| Fenofibrate, colchicine, or niacin at 1 g a day or more | Muscle risk adds up | Prescriber weighs benefit against risk 1 |
| Antacids with aluminum and magnesium hydroxide | About half as much rosuvastatin is absorbed | Take rosuvastatin at least 2 hours before the antacid 1 |
| Grapefruit | Little effect expected, since rosuvastatin barely uses CYP3A4 | No label limit |
Even a short course of an interacting medicine, such as a new HIV or hepatitis C regimen or cyclosporine after a transplant, can push rosuvastatin over its limit. The label's full list is longer, so mention rosuvastatin to the pharmacist whenever a new medicine starts. Niacin at cholesterol-lowering doses is one of the add-ons the label flags for muscle risk 1. Alcohol has no direct interaction with rosuvastatin, but the label warns that people who drink substantial amounts or have had liver disease may be at higher risk of liver injury 1.
The US label advises stopping rosuvastatin once pregnancy is recognized, unless the prescriber judges that the person's ongoing heart risk calls for continuing, and advises against breastfeeding on it 1. Pregnancy is no longer listed as an absolute bar to the drug 1. Anyone on rosuvastatin who becomes pregnant, or plans to, should tell the prescriber straight away.
When LDL is still too high on rosuvastatin
The 2026 ACC/AHA guideline, which replaced the 2018 one in March 2026, sets LDL goals by risk, down to under 55 mg/dL (1.4 mmol/L) for people with heart or artery disease at very high risk 7. When a statin alone does not reach the goal, it adds a non-statin: ezetimibe, a tablet that blocks cholesterol absorption in the gut; bempedoic acid, a tablet that acts one step earlier than statins in the same cholesterol pathway; or an injectable PCSK9 inhibitor such as evolocumab, which leaves more LDL receptors on liver cells 7.
RACING tested the ezetimibe pairing directly in 3,780 adults in South Korea with heart or artery disease caused by plaque (atherosclerotic disease): rosuvastatin 10 mg plus ezetimibe 10 mg matched rosuvastatin 20 mg alone 6.
| Over 3 years in RACING | Rosuvastatin 10 mg plus ezetimibe | Rosuvastatin 20 mg alone |
|---|---|---|
| Cardiovascular death, major cardiovascular event or stroke | 9.1% 6 | 9.9% 6 |
| LDL under 70 mg/dL | 72% 6 | 58% 6 |
| Stopped or cut the dose because of side effects | 4.8% 6 | 8.2% 6 |
Add-on drugs lower what is left, so their percentages multiply rather than add; the atorvastatin guide works through the arithmetic. Foods that lower cholesterol covers diet changes with trial evidence.
The blood tests that go with rosuvastatin
The 2026 guideline recommends a lipid panel within 12 weeks of starting a statin or changing its dose, to check the response and whether the tablets are being taken, then about once a year 7; since the full effect takes about 4 weeks, 4 to 12 weeks reads it fairly 1. On 20 or 40 mg, the expected result is an LDL at least 50 percent below the pre-treatment value 2, so keep the panel from before starting. Your own drop is the LDL before minus the LDL after, divided by the LDL before, times 100: 160 down to 80 mg/dL is 50 percent.
Example: where a percentage LDL drop falls on the intensity bands% LDL drop from the pre-treatment panel
| When | Tests | What they show |
|---|---|---|
| Before starting | Lipid panel (with ApoB if available), lipoprotein(a) once if never measured, ALT, creatinine with eGFR, HbA1c or fasting glucose; CK if there were past muscle problems; TSH (thyroid-stimulating hormone, the main thyroid test) if an underactive thyroid is suspected | The baseline every later result is compared with; eGFR also sets the starting dose 1 7 |
| 4 to 12 weeks after starting or a dose change | Lipid panel | Your own percentage drop, and whether the dose reaches its intensity 7 |
| About once a year after that | Lipid panel | Whether the response holds 7 |
| When the prescriber advises, especially if it was borderline | HbA1c | The small rise in blood sugar rosuvastatin can cause 1 |
| Only for symptoms or a finding | ALT, CK, urine protein | Liver symptoms, muscle aches, or a positive urine dipstick 1 |
LDL goals depend on risk. The 2026 guideline sets them at under 100 mg/dL (2.6 mmol/L) at borderline or intermediate risk, under 70 mg/dL (1.8 mmol/L) at high risk and under 55 mg/dL (1.4 mmol/L) at very high risk 7; what an LDL of 70 means covers the most common one. If LDL barely moves, missed doses, a draw taken too soon and ordinary variation are common reasons, and the prescriber can work out which applies. In familial hypercholesterolemia the percentage drop is usually similar, but LDL can stay well above goal because it started so high.
Markers to read on rosuvastatin
CalculatorLDL calculatorRecalculates LDL from total cholesterol, HDL and triglycerides with the Martin-Hopkins equation, a newer formula that stays accurate at low LDL, as well as the older Friedewald formula, which matters once rosuvastatin brings LDL low.Work it out Free, no accountRead your blood testHave a lipid panel from before rosuvastatin and one from after? Read every line of both, free, and see your own percentage drop.Read my results 
How to read your lipid panel walks through each line of the report, the cholesterol converter turns mg/dL into mmol/L, and the heart health guide puts lipids beside blood pressure and blood sugar.
Citations
- CRESTOR (rosuvastatin) tablets, US prescribing information and patient information, revised 09/2026. AstraZeneca. DailyMed, US National Library of Medicine
- Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 2019;139:e1082-e1143
- Jones PH et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). American Journal of Cardiology, 2003;92(2):152-160
- Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine, 2008;359:2195-2207
- Lee YJ et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ, 2023;383:e075837
- Kim BK et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING). The Lancet, 2022;400:380-390
- Blumenthal RS, Morris PB et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. JACC, 2026;87(19):2624-2757
- Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet, 2022;400:832-845
- Yusuf S et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease (HOPE-3). New England Journal of Medicine, 2016;374:2021-2031
- Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database of Systematic Reviews, 2014;(11):CD010254
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 2010;376:1670-1681
- Nissen SE et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis (ASTEROID). JAMA, 2006;295(13):1556-1565
- Tsimikas S et al. Statin therapy increases lipoprotein(a) levels. European Heart Journal, 2020;41(24):2275-2284
- Cholesterol Treatment Trialists' Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet Diabetes & Endocrinology, 2024;12:306-319
- Cooper-DeHoff RM et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clinical Pharmacology & Therapeutics, 2022;111(5):1007-1021
- Lipitor (atorvastatin calcium) tablets, US prescribing information, revised 12/2022. DailyMed, US National Library of Medicine
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.








